REMEDIO
REspiratory MEDicines Improved and Optimized
Scheda del progetto
REMEDIO designs nanomedicine-based inhalation therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and interstitial lung disease associated with systemic sclerosis (SSc-ILD), with the goal of improving efficacy and reducing side effects compared to current oral therapies. It uses innovative systems to localize the therapy at the pulmonary level and enable a greater deposition of active ingredients at the alveolar level.
REMEDIO involves the participation of the innovative start-up ADA which has expertise in the design of drug delivery systems, and will collaborate with UPO and APTsol to test formulations and conduct pilot trials of spray drying.
Contact:
Alessandro Marengo
alessandromarengo@ada.srl ; info@ada.srl
The REMEDIO project will develop inhalation therapies for the treatment of SSc-ILD and IPF, improving efficacy and reducing the side effects of current therapies. It will use nanostructured systems to localise treatment at the pulmonary level, also enabling the development of combination therapies.
It will address significant technological and pharmaceutical challenges such as the design of inhalation powders and the design of molecules that, when appropriately modified, combine therapeutic activity with carrier functions featuring mucopenetrating properties. The project aims to satisfy a market worth 4.6 billion dollars. SMART objectives include the validation of formulations, the production of inhalation powders and the digitalization of processes.
Currently, inhalation therapies represent only 1.24% of the total drugs approved by the FDA. The REMEDIO project innovates the treatment of IPF and SSc-ILD by proposing the shift from systemic to local therapy through inhalation therapies based on nanomedicine. It designs combination therapies, offering significant therapeutic advantages. The technology, already validated in the laboratory (TRL4) aims at the TRL5 through industrial pilot tests.
The project offers scientific impacts by innovating the treatment of IPF and of SSc-ILD and improving new insights into pulmonary diseases. Economically, it reduces Research and Development costs through pharmaceutical reformulation activities. Socially, it improves the care of rare diseases, generates scientific evidence for patents, promotes the emplyment of specialized resources, and facilitates the industrialization of results. The therapies developed in REMEDIO have the potential to replace existing treatments due to their favorable benefit-risk ratio, with a lower impact on the national healthcare system, as reduced side effects and increased efficacy decrease the risk oh hospitalization.
Additionally, inhalation therapy may enhance patient adherence to treatment.